Clinical study of Pai-Neng-Da capsule (派能达胶囊) in the treatment of chronic aplastic anemia

Yue-min Kuang; Yan Zhu; Rui-lan Gao; Jing Hu; Zhi-yong Jiang; Li Huang; Ya-jun Tong; Xin-guo Luo; Xin-fang Gao; Zhi-yin Zheng

doi:10.1007/s11655-015-2158-6

Your Location：

Home >

Browse articles >

Clinical study of Pai-Neng-Da capsule (派能达胶囊) in the treatment of chronic aplastic anemia

Updated：2021-08-27

- Clinical study of Pai-Neng-Da capsule (派能达胶囊) in the treatment of chronic aplastic anemia
- Chinese Journal of Integrative Medicine Vol. 22, Issue 2, Pages: 124-129(2016)
- Affiliations：
  
  1. Department of Hematology, Jinhua People’s Hospital,Zhejiang Province,Jinhua,China
  2. Institution of Hematology Research, The First Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou,China
  3. Jinhua Medical College, Jinhua Polytechnic,Zhejiang Province,Jinhua,China
  4. Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou,China
- Author bio：
- Funds：
  
  Supported by the Science and Technology Program of Zhejiang Province, China (Public Welfare Technology Applied Research, No. 2010C33098) and Science and Technology Division of Jinhua Municipal Government (No. 11-3-013)
- DOI：10.1007/s11655-015-2158-6
  CLC：
- Published：2016，
  
  Published Online：14 August 2015，
Scan for full text
Kuang, Ym., Zhu, Y., Gao, Rl. et al. Clinical study of Pai-Neng-Da capsule (派能达胶囊) in the treatment of chronic aplastic anemia., Chin. J. Integr. Med. 22, 124–129 (2016). https://doi.org/10.1007/s11655-015-2158-6

Yue-min Kuang, Yan Zhu, Rui-lan Gao, et al. Clinical study of Pai-Neng-Da capsule (派能达胶囊) in the treatment of chronic aplastic anemia. [J]. Chinese Journal of Integrative Medicine 22(2):124-129(2016)
Kuang, Ym., Zhu, Y., Gao, Rl. et al. Clinical study of Pai-Neng-Da capsule (派能达胶囊) in the treatment of chronic aplastic anemia., Chin. J. Integr. Med. 22, 124–129 (2016). https://doi.org/10.1007/s11655-015-2158-6 DOI：

Yue-min Kuang, Yan Zhu, Rui-lan Gao, et al. Clinical study of Pai-Neng-Da capsule (派能达胶囊) in the treatment of chronic aplastic anemia. [J]. Chinese Journal of Integrative Medicine 22(2):124-129(2016) DOI： 10.1007/s11655-015-2158-6.

摘要

To evaluate the effificacy and safety of Pai-Neng-Da Capsule (派能达胶囊

panaxadiol saponins component

PND)

a new Chinese patent medicine

on patients with chronic aplastic anemia (CAA) and to explore the optimal therapeutic regimen for CAA. A total of 36 patients with CAA were enrolled and divided into three groups: the AP group (20 cases

andriol 120 mg/day + PND 240 mg/day)

the ACP group (13 cases

andriol 120 mg/day + cyclosporine 3–6 mg kd-1 day-1 + PND 240 mg/day)

and the PND group (3 cases

PND 240 mg/day). All patients were treated and followed up for 6 months. Peripheral blood counts

renal and hepatic function and Chinese medical (CM) symptoms of patients were assessed and all indices were gathered at the beginning and end of the study. In the AP group

no signifificant hematologic difference was observed at the end of 6-month treatment comparing with the beginning. In the ACP group

the blood counts were maintained at the same level after the 6-month treatment. In the PND group

trilineage hematologic improvement was displayed at the end of 6-month treatment comparing with the beginning. No significant difference was showed in renal and hepatic function in all patients. All patients’ clinical symptom improved according to CM symptom score. The effective rates were 95%

73% and 100%

respectively. PND improved the effificacy and decreased side effects by cutting down the dosage of andriol

and it could also improve patients’ clinical symptom and quality of life. PND were effective and safe in the treatment of CAA

it could be used alone or in combination with pharmacological agents such as andriol and cyclosporine.

Abstract

To evaluate the effificacy and safety of Pai-Neng-Da Capsule (派能达胶囊

panaxadiol saponins component

PND)

a new Chinese patent medicine

andriol 120 mg/day + PND 240 mg/day)

the ACP group (13 cases

andriol 120 mg/day + cyclosporine 3–6 mg kd-1 day-1 + PND 240 mg/day)

and the PND group (3 cases

PND 240 mg/day). All patients were treated and followed up for 6 months. Peripheral blood counts

renal and hepatic function and Chinese medical (CM) symptoms of patients were assessed and all indices were gathered at the beginning and end of the study. In the AP group

no signifificant hematologic difference was observed at the end of 6-month treatment comparing with the beginning. In the ACP group

the blood counts were maintained at the same level after the 6-month treatment. In the PND group

73% and 100%

respectively. PND improved the effificacy and decreased side effects by cutting down the dosage of andriol

and it could also improve patients’ clinical symptom and quality of life. PND were effective and safe in the treatment of CAA

it could be used alone or in combination with pharmacological agents such as andriol and cyclosporine.

关键词

chronic aplastic anemianew Chinese Patent medicinepanaxadiol saponins component

Keywords

chronic aplastic anemianew Chinese Patent medicinepanaxadiol saponins component

references

Gao RL, Chong BH. Research and development of the effective components of Panaxadiol saponin as new Chinese patent medicine for treating hemocytopenia. Chin J Integr Med 2012;18:892–897.

Zhang ZN, Shen T, eds. Standard for diagnosis and therapeutic efficacy evaluation of hematopathy. 3rd ed. PubIishing House of Science; 2007:19–23.

Zheng XY, ed. Guiding principle of clinical research on new drugs of traditional Chinese medicine. Beijing: China Medical Science and Technology Press; 2002:177–180.

Gao RL, Xu CL, Jin JM. Effect of total saponins of Panax ginseng on hematopoietic progenitor cells in normal human and aplastic anemia patients. Chin J Integr Tradit West Med (Chin) 1992;12:285–287.

Qian XD, Ma FS, Gao RL. Efficacy observation of Sheng-Xue-Ling capsules (total saponins of Panax ginseng) in treating chronic aplastic anemia. J Zhejiang Clin Med (Chin) 2004;6:952–953.

Shen YP, Zhou YH, Yu RX. Clinical observation of total saponins of Panax ginseng in combination with cyclosporin A for treatment of chronic aplastic anemia. J Zhejiang Med (Chin) 2001;23:178–179.

Ma FS, Gao RL, Lin XJ, Xu JL, Miao Q, Chen XH, et al. Clinical research of Shengxueling Capsule (total ginsenosides) for treatment of immune thrombocytopenia. J Zhejiang Chin Med Univ (Chin) 2012;36:137–140.

Shao KD, Zhou YH, Shen YP, Ye BD, Gao RL, Zhang Y. Treatment of 37 patients with refractory idiopathic thrombocytopenic purpura by Shengxueling. Chin J Integr Med 2007;13:33–38.

Zhou YH, Yu RX, Luo XS. Clinical observation of total saponins of Panax ginseng in treating neutrophil granulocytopenia. Chin J Integr Tradit West Med (Chin) 2000;20:539–540.

Gao RL. Research and development new Chinese materia medica for treatment of refractory hematopathy by establishment and application multiple technique platforms. Chin J Integr Med 2007;13:95–97.

Fang GL, Gao RL, Lin XJ, Jin JM. Effects of ginseng panaxadiol saponin on proliferation and differentiation of human bone marrow CD34+ cells. Chin J Integr Tradit West Med (Chin) 2007;15:776–779.

Gao RL, Ma FS, Wu CQ, Xu JL, Chong BH. Panax ginsenosides for treating refractory blood diseases as well as up regulation and transcription of genes in relationship with hematopoiesis. Bull Med Res (Chin) 2002;31:23–24.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Clinical study on effect of Astragalus Injection (黄芪注射液) and its immuno-regulation action in treating chronic aplastic anemia

Role of heteroplasmic mutations in the mitochondrial genome and the ID4 gene promoter methylation region in the pathogenesis of chronic aplastic anemia in patients suffering from Kidney yin deficiency

Ginseng-Derived Panaxadiol Saponins Promote Hematopoiesis Recovery in Cyclophosphamide-Induced Myelosuppressive Mice: Potential Novel Treatment of Chemotherapy-Induced Cytopenias

Related Author

No data

Related Institution

TCM Hospital of Langfang City, Chinese Hemopathic Therapeutic Center of TCM

Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Postdoctoral Research Station, Shandong University

Department of Hematology, Shangdong Province Hospital of Shandong University

Department of Oncology, The Second Affiliated Hospital, Medical College of Zhejiang University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰